Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: Stability at room temperature and implications for application in the screening setting [15]

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 782-784

  Haug, Ulrike ^a,b   Wente, Moritz N ^c   Seiler, Christoph M ^c   Rothenbacher, Dietrich ^a,b   Büchler, Markus W ^c   Brenner, Hermann ^b  

^a GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; UNCLASSIFIED DRUG;

CANCER SCREENING; CLINICAL ARTICLE; CLINICAL LABORATORY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; LABORATORY TEST; LETTER; REGRESSION ANALYSIS; ROOM TEMPERATURE;

COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; PYRUVATE KINASE; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645460225     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.062752     Document Type: Letter

References (10)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, Ver. 2.0. Lyon: IARC Press, 2004. http://www-dep.iarc.fr/ (accessed October 30, 2005).
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Haug U, Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer 2005;117:169-76.
4. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004;91:980-4.
5. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 2002;87(Suppl 1):23-9.
6. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003;23:851-3.
7. Rothenbacher D, Löw M, Hardt PD, Klor HU, Ziegler H, Brenner H. Prevalence and determinants of exocrine pancreatic insufficiency among older adults: results of a population-based study. Scand J Gastroenterol 2005;40:697-704.
8. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 2-correlation between subjects [Erratum published in BMJ 1996;312:572]. BMJ 1995;310:663.
9. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-74.
10. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst 2002;94:1743-72.